GSK's Cervarix may have been the first HPV shot approved in mainland China, but Merck's Gardasil now has an opening to gain the lead.
Dead set on defending its top drug, Johnson & Johnson is taking South Korea’s Samsung Bioepis to federal court over a biosim launch.
Rocked by a corruption scandal in Korea, Novartis is working to strengthen and simplify its global ethics and compliance approach.
Takeda’s plan to launch a Hib vaccine in Japan has ended in smoke as GlaxoSmithKline has terminated production of Vaxem Hib.
Novartis is learning about its kickbacks punishment in South Korea as authorities decided to issue a fine of nearly $50 million.
Johnson & Johnson has kept a positive attitude about its blockbuster immunology drug Remicade and the biosimilar competition it’s facing.
Sanofi Pasteur's dengue vaccine Dengvaxia will have to undergo phase 4 testing in Malaysia.
Takeda’s IBD Superheroes ad is pharma’s North Carolina Tarheels, winning the championship in our first DTC advertising tournament.
In what could be a direct rebuttal to President Donald Trump’s view on foreign trade, Eli Lilly CEO David Ricks called any promotion of deglobalization “…
Mylan and Biocon today won a court ruling that said they may sell their Herceptin biosimilar in India where it was first introduced three years ago.